Skip to content

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting in Overweight and Obese Human Subjects and the Impact of Growth Hormone Receptor Blockade

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02500095
Enrollment
10
Registered
2015-07-16
Start date
2015-07-31
Completion date
2016-11-30
Last updated
2016-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Background: Calorie restriction increases longevity in many species and attenuate the development of chronic disorders including type 2 diabetes, cardiovascular diseases and cancer. In mice reduced activity of insulin-like growth factor I (IGF-I) and/or insulin is associated with extended longevity. Growth hormone (GH) is the main regulator of IGF-I production, but the molecular mechanism whereby GH switches from IGF-I stimulation (protein anabolism) to fatty acid oxidation (fatty acid catabolism) as well as induction of insulin resistance during fasting remains enigmatic. Hypotheses: The changes of the global set of metabolites, induction of insulin resistance, and the shift in metabolism from protein anabolism to lipolysis together with the potentially favorable effect of calorie restriction during fasting depend on preserved fasting-induced GH secretion. Aim: The investigators wish to provide knowledge on changes in metabolites and shift in signaling pathways that take place at the transition to the fasting state among healthy overweight and obese subjects. Furthermore the investigators wish to determine the effect of GH on the adaption of the metabolism to a fasting state.

Interventions

OTHERFasting

72 hours of fasting

DRUGSaline

Concomitant saline during fasting

DRUGPegvisomant

Concomitant Growth hormone receptor blockade with Pegvisomant during fasting

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy men * written consent * body mass index (BMI) 25-40 * age 20-60 years

Exclusion criteria

* any kind of disease * regular medication

Design outcomes

Primary

MeasureTime frameDescription
Insulin and growth hormone signaling, expressed as CHANGE in phosphorylation of intracellular target proteins and CHANGE in messenger ribonucleic acid (mRNA) expression of target genes in muscle- and fat-tissue.Muscle and fat biopsies obtained at t1= 9.00 am (60 min) and t2=12.30 am (270 min) on each study day after 0, 4 and 8 weeks (interval of 4 weeks between each of the three study days)Change in phosphorylation of target proteins and mRNA expression of target genes

Secondary

MeasureTime frameDescription
Glucose metabolismChange in glucose metabolism using glucose tracer from t=0 min - 360 min on each study day after 0, 4 and 8 weeks (interval of 4 weeks between each of the three study days)Change in glucose metabolism assessed by tracer kinetics on every study day and by indirect calorimetry.
Magnetic resonance (MR) spectroscopyDuring fasting: t= 12 hours and t= 48 hours of fasting
Change in concentrations of metabolites in the insulin and growth hormone signaling pathways using metabolomicsMuscle-tissue obtained at t1= 9.00 am (60 min) and t2=12.30 am (270min) on each study day after 0, 4 and 8 weeks (interval of 4 weeks between each of the three study days)Method: Metabolomics
Fat metabolismChange in fat metabolism using palmitic acid tracer from t1=180 min - 240 min and t2=300 min - 360 min on each study day after 0, 4 and 8 weeks (interval of 4 weeks between each of the three study days)Change in fat metabolism assessed by tracer kinetics on every study day and by indirect calorimetry.
Protein metabolismChange in protein metabolism using urea tracer from t=0 min - 240 min on each study day after 0, 4 and 8 weeks (interval of 4 weeks between each of the three study days)Change in protein metabolism assessed by tracer kinetics on every study day and by indirect calorimetry.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026